Charles Schwab Investment Management Inc. Boosts Position in Genmab A/S (NASDAQ:GMAB)

Charles Schwab Investment Management Inc. lifted its holdings in shares of Genmab A/S (NASDAQ:GMAB) by 94.1% in the third quarter, Holdings Channel.com reports. The fund owned 26,104 shares of the company’s stock after purchasing an additional 12,654 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Genmab A/S were worth $636,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. DDD Partners LLC purchased a new position in Genmab A/S during the 2nd quarter valued at $8,860,000. Cubist Systematic Strategies LLC increased its position in shares of Genmab A/S by 109.7% during the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after buying an additional 145,689 shares during the period. Renaissance Technologies LLC raised its stake in Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after buying an additional 103,859 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in Genmab A/S in the second quarter worth about $1,354,000. Finally, Ingalls & Snyder LLC boosted its position in Genmab A/S by 29.3% during the 2nd quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock valued at $5,772,000 after acquiring an additional 52,117 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Up 0.5 %

Shares of GMAB opened at $20.14 on Thursday. Genmab A/S has a twelve month low of $19.85 and a twelve month high of $32.88. The company has a market capitalization of $13.33 billion, a P/E ratio of 19.55, a price-to-earnings-growth ratio of 0.67 and a beta of 0.96. The firm has a 50 day moving average of $21.94 and a 200 day moving average of $24.90.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The business had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same period in the previous year, the business posted $0.47 EPS. On average, sell-side analysts expect that Genmab A/S will post 1.28 EPS for the current year.

Analysts Set New Price Targets

GMAB has been the subject of several research reports. Truist Financial decreased their target price on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Wednesday, October 16th. Morgan Stanley restated an “equal weight” rating and issued a $31.00 price objective on shares of Genmab A/S in a report on Wednesday, September 11th. BMO Capital Markets reiterated an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Finally, Redburn Atlantic began coverage on Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.